Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Kaposi 3Epstein-Barr Virus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Immune Reconstitution Inflammatory Syndrome 1Cytomegalovirus Infections 1Castleman Disease 1

Interventions

blinatumomab 6Cyclophosphamide 5Rituximab 4Tacrolimus 3ponatinib 2fludarabine 2denileukin diftitox 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Everolimus 2Etoposide 2Doxorubicin 2Darbepoetin alfa 2Cytarabine 2Busulfan 2Brentuximab Vedotin 2Antilymphocyte Serum 2Alemtuzumab 2tetulomab tetraxetan lu-177 1ruxolitinib 1pembrolizumab 1pegaspargase 1ibrutinib 1ibritumomab tiuxetan 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoproliferative Disorders × Valganciclovir × Clear all
NCT03397706 2025-03-20

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Viracta Therapeutics, Inc.

Phase 1/2 Completed
64 enrolled 31 charts
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡